A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

September 5, 2025

Study Completion Date

September 5, 2025

Conditions
Asthma
Interventions
DRUG

Salbutamol HFA-134a

100 microgram (μg) (ex-valve) at 30-second intervals per actuation

DRUG

Salbutamol HFA-152a

100 μg (ex-valve) at 30-second intervals per actuation

Trial Locations (104)

1900

GSK Investigational Site, La Plata

2019

GSK Investigational Site, Botany

2259

GSK Investigational Site, Kanwal

2450

GSK Investigational Site, Coffs Harbour

5000

GSK Investigational Site, Iloilo City

6163

GSK Investigational Site, Spearwood

7002

GSK Investigational Site, Panama City

7099

GSK Investigational Site, Panama City

10128

GSK Investigational Site, Torino

11220

GSK Investigational Site, Brooklyn

12120

GSK Investigational Site, Pathum Thani

15241

GSK Investigational Site, Pittsburgh

15669

GSK Investigational Site, Athens

15706

GSK Investigational Site, Santiago de Compostela

19107

GSK Investigational Site, Philadelphia

19464

GSK Investigational Site, Pottstown

20162

GSK Investigational Site, Milan

21100

GSK Investigational Site, Tradate VA

27104

GSK Investigational Site, Winston-Salem

28031

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28223

GSK Investigational Site, Pozuelo de AlarcOn Madr

28803

GSK Investigational Site, Asheville

29303

GSK Investigational Site, Spartanburg

29379

GSK Investigational Site, Union

29603

GSK Investigational Site, Marbella

29631

GSK Investigational Site, Benalmádena

29732

GSK Investigational Site, Rock Hill

30038

GSK Investigational Site, Stonecrest

31326

GSK Investigational Site, Rincon

32720

GSK Investigational Site, DeLand

32789

GSK Investigational Site, Winter Park

33144

GSK Investigational Site, Miami

33155

GSK Investigational Site, Miami

33173

GSK Investigational Site, Miami

33180

GSK Investigational Site, Aventura

33317

GSK Investigational Site, Plantation

33756

GSK Investigational Site, Clearwater

34102

GSK Investigational Site, Naples

35128

GSK Investigational Site, Padua

37134

GSK Investigational Site, Verona

38654

GSK Investigational Site, Olive Branch

40217

GSK Investigational Site, Louisville

41110

GSK Investigational Site, Larissa

42301

GSK Investigational Site, Owensboro

43016

GSK Investigational Site, Dublin

45231

GSK Investigational Site, Cincinnati

50134

GSK Investigational Site, Florence

55402

GSK Investigational Site, Minneapolis

56001

GSK Investigational Site, Minneota

57010

GSK Investigational Site, Thessaloniki

65203

GSK Investigational Site, Columbia

67091

GSK Investigational Site, Strasbourg

71100

GSK Investigational Site, Foggia

77375

GSK Investigational Site, Tomball

77479

GSK Investigational Site, Sugar Land

80054

GSK Investigational Site, Amiens

80131

GSK Investigational Site, Napoli

80909

GSK Investigational Site, Colorado Springs

86021

GSK Investigational Site, Poitiers

89052

GSK Investigational Site, Henderson

94010

GSK Investigational Site, Créteil

94403

GSK Investigational Site, San Mateo

95100

GSK Investigational Site, Argenteuil

95303

GSK Investigational Site, Pontoise

97504

GSK Investigational Site, Medford

91606-3287

GSK Investigational Site, North Hollywood

02723

GSK Investigational Site, Fall River

07306

GSK Investigational Site, Jersey City

07457

GSK Investigational Site, Riverdale

C1425AZE

GSK Investigational Site, Buenos Aires

C1425BEN

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

M5500CCG

GSK Investigational Site, Mendoza

L1S 2J5

GSK Investigational Site, Ajax

L6T 0G1

GSK Investigational Site, Brampton

K1H 1E4

GSK Investigational Site, Ottawa

M9V 4B4

GSK Investigational Site, Toronto

N8X 2G1

GSK Investigational Site, Windsor

G1V 4W2

GSK Investigational Site, Québec

G1W 4R4

GSK Investigational Site, Québec

06614

GSK Investigational Site, Cannes

09042

GSK Investigational Site, Cagliari

Unknown

GSK Investigational Site, Roma

GSK Investigational Site, Panama City

15-010

GSK Investigational Site, Bialystok

43-300

GSK Investigational Site, Bielsko-Biala

41-500

GSK Investigational Site, Chorzów

82-300

GSK Investigational Site, Elblag

40-600

GSK Investigational Site, Katowice

27-400

GSK Investigational Site, Ostrowiec Świętokrzyski

09-407

GSK Investigational Site, Płock

33-100

GSK Investigational Site, Tarnów

08017

GSK Investigational Site, Barcelona

08540

GSK Investigational Site, Barcelona

CH63 9JP

GSK Investigational Site, Bebington

CB7 5JD

GSK Investigational Site, Cambridgeshire

NN17 2UR

GSK Investigational Site, Corby

OL6 6HD

GSK Investigational Site, Greater Manchester

TS14 7DJ

GSK Investigational Site, Guisborough

TW3 3EL

GSK Investigational Site, Hounslow

LL18 4HZ

GSK Investigational Site, Rhyl

ST14 5JX

GSK Investigational Site, Uttoxeter

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06261957 - A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma | Biotech Hunter | Biotech Hunter